Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue $ 0 $ 0
Expenses:    
Research and development 8,811 7,393
General and administrative 5,285 4,107
Operating expenses 14,096 11,500
Other income/(expense):    
Interest income 422 22
Foreign exchange loss (2) (3)
Total other income 420 19
Net loss (13,676) (11,481)
Other comprehensive income:    
Unrealized gain/(loss) on available-for-sale securities 4 0
Total comprehensive loss $ (13,672) $ (11,481)
Basic loss per common share (in dollars per share) $ (0.15) $ (0.12)
Diluted loss per common share (in dollars per share) $ (0.15) $ (0.12)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 92,562 92,226
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares) 92,562 92,226